JMP Securities began coverage on shares of PLx Pharma (NASDAQ:PLXP) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. ValuEngine downgraded PLx Pharma from a hold rating to a sell rating in a research note on Friday, January 25th. Zacks Investment Research downgraded PLx Pharma from a hold rating to a sell rating in a research note on Tuesday, January 1st. Finally, Raymond James downgraded PLx Pharma from an outperform rating to a market perform rating in a research note on Monday, January 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $9.38.

PLXP stock opened at $5.91 on Thursday. The stock has a market capitalization of $50.67 million, a P/E ratio of -4.38 and a beta of 5.33. PLx Pharma has a 52 week low of $1.00 and a 52 week high of $6.60. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.14 and a quick ratio of 4.84.

PLx Pharma (NASDAQ:PLXP) last posted its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.06. The business had revenue of $0.29 million during the quarter. PLx Pharma had a negative return on equity of 186.01% and a net margin of 1.09%. On average, sell-side analysts predict that PLx Pharma will post -1.15 earnings per share for the current fiscal year.

In related news, major shareholder Park West Asset Management Llc purchased 397,495 shares of the company’s stock in a transaction that occurred on Thursday, December 27th. The stock was acquired at an average price of $1.00 per share, with a total value of $397,495.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.21% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Park West Asset Management LLC raised its stake in PLx Pharma by 37.0% during the fourth quarter. Park West Asset Management LLC now owns 1,473,218 shares of the biotechnology company’s stock worth $2,254,000 after acquiring an additional 397,495 shares in the last quarter. Vanguard Group Inc. raised its stake in PLx Pharma by 98.0% during the third quarter. Vanguard Group Inc. now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after acquiring an additional 80,910 shares in the last quarter. Finally, Vanguard Group Inc raised its stake in PLx Pharma by 98.0% during the third quarter. Vanguard Group Inc now owns 163,431 shares of the biotechnology company’s stock worth $662,000 after acquiring an additional 80,910 shares in the last quarter. 24.27% of the stock is owned by hedge funds and other institutional investors.

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

See Also: What is a Swap?

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.